Zurich (ots) - In 2019, medication costs in Switzerland totalled approximately CHF 7.6 billion. The front runners remained cancer and immune system drugs, followed by nervous system medications and metabolic preparations. The use of biosimilars (generic preparations) offers significant savings potential that unfortunately remains almost completely unexploited. In an ...
Zürich (ots) - In 2019, Helsana Insurance Company Ltd recorded an outstanding result of CHF 436 million. This comprises a very strong investment performance and a solid underwriting result. Customer growth for 2020 once again clearly exceeded the prior year and the new corporate strategy was successfully launched at the start of 2020. In 2019, Helsana Insurance Company Ltd recorded an outstanding result of CHF 436 ...
Zurich (ots) - The medication costs in Switzerland amounted to about CHF 7.6 billion in 2018. Since 2010, costs have risen by 46 percent, whereby half of this increase was attributable to immunosuppressants and cancer medication. Great savings potential is above all associated with the use of biosimilars. One of the other findings of this year's Helsana Drug Report is ...
Zürich (ots) - The "Volume Report" published today by Helsana elucidates the development of medical treatments. In Switzerland, increasing numbers of patients make use of medical treatments. As a result there is an increased need for coordination. General practitioners have less and less time to perform this role. The report finds great potential to meet these coordination needs in other health occupations. In its latest ...